News

Recommended tags

+ More Filters

Indication

Solid Tumors ^× Lung Cancer Prostate Cancer Ovarian Cancer

Product Candidates

BOXR1030 DCVAC/LuCa ^× DCVAC/OvCa DCVAC/PCa nanrilkefusp alfa SOT106 SOT109 SOT201

Release Type

Corporate ^× Investments Partnering

NEWS June 2, 2019

SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer

DCVAC/LuCa decreased the risk of death in patients with stage IV NSCLC by 46%
Median overall survival (OS) reached 15.5 months in the treatment arm compared to 11.8 months in the control arm
Median Progression Free Survival (PFS) prolonged by 1.1 months
Final results of OS and PFS are statistically significant
SOTIO considers initiation of Phase II/III clinical trials with DCVAC/LuCa

SOTIO, a biotechnology company owned by the PPF Group, presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa. SLU01 clinical trial results were presented by the principal investigator Libor Havel, MD, from Thomayer University Hospital in Prague (Czech Republic) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today.

NEWS May 20, 2019

SOTIO to Present Final Phase I/II DCVAC/LuCa Data at ASCO 2019 Annual Meeting

SOTIO, a biotechnology company owned by the PPF Group, today announces that final data from the SLU01 Clinical Trial with DCVAC/LuCa will be presented in poster session at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2019. Final analysis of SLU01 data confirmed promising clinical efficacy of DCVAC/LuCa active cellular immunotherapy product in patients with stage IV non-small cell lung cancer.

NEWS June 4, 2018

Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer

Chicago/Prague - SOTIO, a biotechnology company owned by the PPF Group, presented results from its Phase II clinical trials evaluating DCVAC, an active cellular immunotherapy product, in patients with ovarian and lung cancer at the 2018 at the American Society of Clinical Oncology (ASCO) Annual Meeting today. The results were statistically and clinically significant and showed that compared to patients who did not receive DCVAC, application of DCVAC/OvCa in patients with ovarian cancer and DCVAC/LuCa in patients with lung cancer decreased the risk of progression or death significantly.

Cookie name	Description	Expiration
BCAPPSESSID3	The BCAPPSESSID3 cookie is native to PHP and enables websites to store serialised state data. It is used to establish a user session and to pass state data via a temporary cookie, which is commonly referred to as a session cookie.	14 days
SSC_COOKIE_*	This cookie stores your decision regarding the storage of cookies in your browser.	2 years

Cookie name	Description	Expiration
_ga	The GA cookie is set, when a person visits your website for the first time. Google Analytics sends the client ID with each hit in order to associate hits with a user. A GA cookie can exist only on the device and browser where it has been set.	2 years
_gid	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing.	24 hours
_gat_gtag_UA_27872723_1	This cookie is used to throttle request rate. These are third party cookies that are placed on your device to allow us to use the Google Analytics service. These cookies are used to collect information about how visitors use our website. We use this information to compile reports and to help us improve the website.	Immediately
AW_VISITOR	Performance cookie to analyze traffic.	1 year

Your privacy

Strictly necessary cookies

Performance cookies

Functional cookies

Targeting and Advertising cookies

More information about Cookies